The filing is a procedural milestone, not a definitive catalyst. Monitor for FDA 510(k) submission and eventual clearance decision. Given the $5M market cap and pre-revenue status, any positive regulatory news could cause significant volatility, but the stock has historically underperformed after similar filings.
Price Chart
Executive Summary
Intelligent Bio Solutions completed precision testing for its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System, confirming reproducibility across 1,600+ tests, three production runs, and three independent sites. This is a positive regulatory milestone but does not yet guarantee FDA clearance or U.S. market entry, and the company remains pre-revenue.
Key Facts
- Precision testing completed for FDA 510(k) submission for detection of opiate codeine
- Over 1,600 tests across three production runs and three independent sites
- Results confirm repeatable, reproducible performance
- No financial data or guidance provided in the filing
- Company has a market cap of ~$5M and is pre-revenue
Financial Impact
No financial data provided in the filing
Risk Factors
- FDA clearance is not guaranteed; the 510(k) submission has not yet been filed
- Pre-revenue company with limited cash runway may require dilutive financing
- U.S. market entry timeline is uncertain and dependent on regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034018 |
| Exhibit: ex99-1.htm | 0001493152-26-034018 |
| Document: 0001493152-26-034018-index-headers.html | 0001493152-26-034018 |
| Document: 0001493152-26-034018-index.html | 0001493152-26-034018 |
| Document: 0001493152-26-034018.txt | 0001493152-26-034018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.68 (−0.00%) |
Oct 13, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $1.68 (+16.21%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.68 (+1.46%) |
Sep 15, 2026 5w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.68 (−14.47%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.68 (−18.60%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.68 (−24.78%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.68 (+26.74%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.68 (−36.89%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.68 (+36.89%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.68 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers